PR Newswire BiotechnologyCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 18:30:00·⟳ 抓取 18:30:20 +20s·⚡ 决策 09-01 18:50:49 +20m29s·56.2 天前
Bio-Techne获SBTi气候目标验证并披露减排进展
该新闻主要改善公司可持续发展披露与ESG形象，但不改变Bio-Techne的收入、成本、产品准入、客户需求或资本结构，行情和先例研究不可能把该类非财务ESG进展转化为明确正期望交易。
📄 原文PR Newswire Biotechnology↗ 原文
Fiscal 2026 highlights: - Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduc…
不做 Bio-Techne Corporation（TECH.US）
不做Bio-Techne Corporation（TECH.US）：公告属于ESG目标验证和减排进展，未带来订单、利润、准入或资本回报增量，缺少短线正期望。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Bio-Techne公告SBTi验证和减排进展，事实本身可信且新鲜，但增量停留在气候目标与用电结构层面；对生命科学试剂、仪器和诊断业务的订单、定价、利润或现金流没有可量化影响。因此不做Bio-Techne Corporation（TECH.US）。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
主要风险
- 若后续客户采购明确把SBTi验证作为大额订单门槛，事件性质才可能从ESG披露转为商业需求催化。
- 当前公告未给出减排投入成本或节约金额，无法量化对利润率的正负影响。
先例如何影响了这次决策
对本次决策的影响:先例不足未改变结论；核心原因是事件缺少收入、利润、准入或资本回报增量。
方向:未使用先例；ESG目标验证公告缺少可交易财务机制，先例即使显示个别波动也难以改变方向。
涨幅量级:没有可用于校准tp/sl的同市场高相似、财务锚明确先例。
形态:未评估见光死模式，因为当前不进入交易。
原文全文
展开原文 · 3,133 字
Fiscal 2026 highlights:
- Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets
- Market-based Scope 1 and 2 emissions reduced 49% year-over-year
- More than half of the company's electricity consumption now comes from renewable sources
- First comprehensive Scope 3 emissions inventory completed
MINNEAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
The SBTi validated Bio-Techne's targets to reduce absolute Scope 1 and 2 greenhouse gas emissions by 70% by fiscal year 2031 from a fiscal year 2025 baseline and to commit that 81% of suppliers by spend covering purchased goods and services, capital goods, upstream transportation and distribution and business travel will have science-based targets by fiscal year 2030.
Validation of the greenhouse gas reduction targets provides customers, suppliers and other stakeholders with independent confirmation that the Company's climate goals are aligned with recognized global standards and climate science.
"Our Science Based Targets validation and progress against those targets demonstrate Bio-Techne's commitment to growing responsibly," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "As we support scientific and diagnostic innovation around the world, we are also taking meaningful steps to reduce our environmental impact and strengthen sustainability across our operations and value chain."
Bio-Techne also expanded its use of renewable electricity during the year. The company transitioned its Minneapolis headquarters to 100% renewable electricity and began procuring renewable electricity for its St. Paul GMP facility. As a result, renewable sources now account for 51% of Bio-Techne's total electricity consumption.
ABOUT BIO-TECHNE
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.
CONTACT:
Corporate Communications
[email protected]
David Clair, Vice President
Investor Relations
[email protected]
SOURCE Bio-Techne Corporation
- Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets
- Market-based Scope 1 and 2 emissions reduced 49% year-over-year
- More than half of the company's electricity consumption now comes from renewable sources
- First comprehensive Scope 3 emissions inventory completed
MINNEAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.
The SBTi validated Bio-Techne's targets to reduce absolute Scope 1 and 2 greenhouse gas emissions by 70% by fiscal year 2031 from a fiscal year 2025 baseline and to commit that 81% of suppliers by spend covering purchased goods and services, capital goods, upstream transportation and distribution and business travel will have science-based targets by fiscal year 2030.
Validation of the greenhouse gas reduction targets provides customers, suppliers and other stakeholders with independent confirmation that the Company's climate goals are aligned with recognized global standards and climate science.
"Our Science Based Targets validation and progress against those targets demonstrate Bio-Techne's commitment to growing responsibly," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "As we support scientific and diagnostic innovation around the world, we are also taking meaningful steps to reduce our environmental impact and strengthen sustainability across our operations and value chain."
Bio-Techne also expanded its use of renewable electricity during the year. The company transitioned its Minneapolis headquarters to 100% renewable electricity and began procuring renewable electricity for its St. Paul GMP facility. As a result, renewable sources now account for 51% of Bio-Techne's total electricity consumption.
ABOUT BIO-TECHNE
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.
CONTACT:
Corporate Communications
[email protected]
David Clair, Vice President
Investor Relations
[email protected]
SOURCE Bio-Techne Corporation
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。